Fig. 7

HuD produces a pro-survival signal. A Viability in stress condition in presence of pan-caspase inhibitor (control or silenced HuD and/or ZDEVD) in IMR-32 cells. B Efficiency of ARL6IP1 for controlling cell viability in IMR-32 cells (control or silenced HuD and/or overexpressed ARL6IP1). C Validation for efficiency of ARL6IP1 in stress condition (control or silenced ARL6IP1) in IMR-32 cells. D Western blot analysis for apoptosis-related protein (control or silenced HuD and/or overexpressed ARL6IP1); serum deprivation was a positive control and relative quantifications shown. Full-length blots are presented in Supplementary Fig. S10. E Viability assay (control or silenced HuD and/or silenced GRB-10 and/or overexpressed ARL6IP1) in IMR-32 and SK-N-SH cells. F Proposed schematic pathway for inhibition of cell death by HuD. G and H Immunostaining of HuD and pS6K in peripheral nerve tissue (PNT) and neuroblastoma (NB) patient of different stages, corresponding stage-wise expression quantification of HuD and pS6K levels are presented. Scale bar corresponds to 200 μm. I Relative mRNA expression quantified by RT-qPCR (control or silenced ND1 and/or active mTORC1 via Rheb S16H construct and/or inactive mTOR via rapamycin-25 nM) in IMR-32 cells. J Relative mRNA expression quantified by RT-qPCR (control or miR375 mimic or miR375 inhibitor) in IMR-32 cells. K Proposed schematic pathway for inhibition of HuD by mTOR. Data are presented as mean ± SEM; t-test: *p < 0.05, **p < 0.01, ***p < 0.001